

A study to compare a single dose of M923, EU-sourced Humira or US-sourced Humira in healthy volunteers

Submission date 11/02/2015	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 16/02/2015	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 02/09/2020	Condition category Other	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

This is a study to investigate and compare the pharmacokinetics (measuring drug levels in the blood over time), safety, tolerability and immunogenicity (blood tests to check the body's immune response to the drug) following single doses (40mg) of three different preparations of a human monoclonal antibody given by injection. This anti-inflammatory human monoclonal antibody is used to treat various autoimmune diseases such as rheumatoid arthritis and psoriasis. Two different preparations are marketed for use in the USA (USHumira) and Europe (EUHumira). Baxter Innovations GmbH (part of The Baxter Healthcare Corporation) is developing a monoclonal antibody M923 to be a similar biological medicinal product (biosimilar) to the marketed adalimumab (USHumira and EUHumira) preparations. M923 has not been given to humans before and in this study will be compared with the 2 marketed USHumira and EUHumira preparations.

Who can participate?

Healthy adults aged 18-55

What does the study involve?

After an initial review of their medical condition to ensure that they meet study requirements to take part, the participants are randomly allocated into one of two groups. Those in group 1 are given a single dose of M923. Those in group 2 are given a single dose of USHumira. Those in group 3 are given a single dose of EUHumira. The study takes place over about 9 months and involves a screening visit, a period where volunteers will be inpatients and must stay in the clinic (up to eight nights), several outpatient visits and a final follow up visit.

What are the possible benefits and risks of participating?

There is no medical benefit to the subjects as they are healthy volunteers. The possibility of side effects from the preparations of Humira and M923 is minimal not only due to the single dose used but also because previous studies with Adalimumab (Humira®) in healthy subjects demonstrated no treatment related serious side effects.

Where is the study run from?

It is a multisite study with three sites in London, Wales, and Northern Ireland

When is the study starting and how long is it expected to run for?

December 2014 to August 2015

Who is funding the study?

Baxter Innovations GmbH (Austria)

Who is the main contact?

Dr Barbara Valenta Singer

barbara_valenta_singer@baxter.com

Contact information

Type(s)

Scientific

Contact name

Dr Barbara Valenta Singer

Contact details

Baxter Innovations GmbH

Donau-City-Strasse 7

Vienna

Austria

1220

+43 (0)1 20100 2472930

barbara_valenta_singer@baxter.com

Additional identifiers

Clinical Trials Information System (CTIS)

2014-001043-20

Integrated Research Application System (IRAS)

164168

Protocol serial number

911301, IRAS 164168

Study information

Scientific Title

A randomized, double-blind, three-arm, parallel group, single-dose study to compare the pharmacokinetics, safety, tolerability, and immunogenicity of three formulations of adalimumab (M923, US Sourced Humira and EU Sourced Humira) in healthy subjects

Study objectives

1. The primary objective is to investigate and compare the pharmacokinetic (PK) profiles of M923, United States of America (US) sourced Humira and European Union (EU) sourced Humira in healthy subjects.
2. The secondary objective is to investigate the safety, tolerability, and immunogenicity of M923, US sourced Humira and EU sourced Humira in healthy subjects.

Ethics approval required

Old ethics approval format

Ethics approval(s)

NRES Committee London - London Bridge, 11/12/2014, ref: 14/LO/2007

Study design

Multi-centre randomised double-blind three-arm parallel-group single-dose study

Primary study design

Interventional

Study type(s)

Other

Health condition(s) or problem(s) studied

Healthy adult volunteers

Interventions

Three formulations of adalimumab (M923, US Sourced Humira and EU Sourced Humira)

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

M923 (adalimumab), US sourced Humira (adalimumab) and EU sourced Humira (adalimumab)

Primary outcome(s)

1. Observed maximum concentration (C_{max})
2. Area under the serum concentration-time curve from time zero to 336 hours [AUC(0-336)]
3. Area under the serum concentration-time curve from time zero extrapolated to infinity [AUC(0-inf)]

PK blood samples will be taken pre-dose and up to and including Day 71 post-dose.

Key secondary outcome(s)

1. The area under the serum concentration-time curve from time zero to 1344 hours [AUC(0-1344)]
2. Area under the serum concentration-time curve from time zero to time of the last quantifiable concentration [AUC(0-last)]
3. Time of maximum concentration (t_{max})
4. Terminal rate constant (λ_z)

5. Terminal half- life ($t_{1/2}$)
6. Apparent volume of distribution following extravascular dosing (V_z/F)
7. Apparent volume of distribution at distribution equilibrium (V_{ss}/F)
8. Apparent systemic clearance after extravascular dosing (CL/F)
9. Area under the concentration-time curve extrapolated from time t to infinity as a percentage of total AUC (%AUC_{ex})

Vital signs will be performed pre-dose and post-dose - ECGs will be performed pre-dose and post-dose. Clinical laboratory tests: pre-dose and post-dose. Adverse events: Day-1 till last visit. Injection site evaluation Day-1 till last visit

Completion date

26/08/2015

Eligibility

Key inclusion criteria

1. Male or females of non-childbearing potential aged 18 to 55 years, inclusive
2. Healthy as determined by pre study medical history, physical examination, vital signs and 12-lead ECG
3. Clinical laboratory test results that are not clinically significant and are acceptable to the investigator at screening and admission to the clinical unit (Day -1)
4. Body weight between 60.0 and 100.0 kg and a body mass index (BMI) between 18.5 and 29.9 kg/m², inclusive
5. Male subjects must have been vasectomized with confirmation of sterility or be willing to comply with the contraception restrictions for this study
6. Female subjects must have a negative pregnancy test at screening and on admission to the clinical unit (Day -1), must not be lactating, and must be of non-childbearing potential
7. Has smoked ≤ 10 cigarettes or 3 cigars or 3 pipes/day for at least 3 months prior to screening and is willing to comply with smoking restrictions during confinement at the study center
8. Willing and able to comply with the requirements of the study
9. Willing and able to sign a written informed consent

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Total final enrolment

324

Key exclusion criteria

1. Clinically significant allergic or hypersensitivity conditions
2. Tuberculosis, invasive systemic fungal infections, other severe opportunistic infections, recent serious infection, recent or recurrent herpes zoster infection, chronic or recurrent infections
3. Recent or planned other investigational trial participation
4. Alcohol abuse or drug abuse
5. Recent use of any prescribed or non prescribed medication other than paracetamol, vitamins and for females, hormone replacement therapy
6. Congestive heart failure
7. Signs or symptoms of demyelinating disease
8. Cancer
9. Impaired liver function
10. Immunodeficiency or other clinically significant immunological disorders
11. Anti-citrullinated protein antibodies at screening
12. Anti-drug antibodies to adalimumab at screening
13. Clinically relevant history or presence of medical disorders as judged by the investigator
14. Recent or planned receipt during the study of a live vaccine
15. Medical dietary restrictions
16. Subjects who cannot communicate reliably

Date of first enrolment

11/12/2014

Date of final enrolment

30/04/2015

Locations**Countries of recruitment**

United Kingdom

England

Northern Ireland

Wales

Study participating centre

Quintiles Drug Research Unit at Guy's Hospital

6 Newcomen Street

London

United Kingdom

SE11YR

Study participating centre

Simbec Research Limited

Pentrebach

Merthyr Tydfil
United Kingdom
CF48 4DR

Study participating centre
Biokinetic Europe
14 Great Victoria Street
Belfast
United Kingdom
BT2 7B

Sponsor information

Organisation
Baxter Innovations GmbH

ROR
<https://ror.org/013xmn143>

Funder(s)

Funder type
Industry

Funder Name
Baxter Innovations

Alternative Name(s)

Funding Body Type
Private sector organisation

Funding Body Subtype
For-profit companies (industry)

Location
Austria

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			28/06/2023	No	No